Zelluna, a biopharmaceutical company founded in 2016, focuses on the development of T-Cell Receptor (TCR) based immunotherapies. The company has several TCRs in different stages of development. Miguel Forte, CEO of Zelluna ImmunotherapAlready a subscriber Login You have read all your free articles, to continue reading subscribe to read the…